Panacea Biotec Limited
All news and filings related to Panacea Biotec Limited.
View all news & filings- Medium impact
Panacea Biotec Ld Holds 42nd AGM on Sep 29, 2026, Voting Results by Oct 1
Panacea Biotec Limited held its 42nd AGM on September 29, 2026, via Video Conference. Key businesses included adopting FY26 financial statements and re-appointing directors. Voting results and the Scrutinizer’s Report are expected by October 1, 2026.
Read the summary - Low impact
Panacea Biotec receives ₹4.32 Crore penalty demand from Income Tax Dept.
Panacea Biotec received two penalty demand orders totaling ₹4.32 Crore from the Income Tax Department for alleged income misreporting for AY 2022-23 & 2023-24. The company disputes the demand and plans to appeal, expecting no significant financial impact.
Read the summary - Medium impact
Panacea Biotec Receives ₹9.82 Crore Tax Penalty Demand Orders
Panacea Biotec received four tax penalty demand orders totaling ₹9.82 Crore for alleged income misreporting. The company disputes the demand and plans to file an appeal, expecting no significant financial or operational impact.
Read the summary - Low impact
Panacea Biotec Limited: Trading Window Closed for Q2 FY27 Results
Panacea Biotec Limited's trading window will be closed from October 01, 2026, pending the announcement of Q2 FY27 financial results. The closure is in line with SEBI regulations. The board meeting date for approving the results will be announced later.
Read the summary - Low impact
Panacea Biotec Reminds Physical Shareholders to Submit PAN & KYC Details
Panacea Biotec Limited is reminding physical shareholders to submit mandatory PAN and KYC details as per SEBI directives. This is crucial for updating records, receiving future payments electronically, and facilitating share dematerialization. Shareholders are urged to comply promptly to avoid service disruptions and ensure smooth transactions.
Read the summary - Low impact
Panacea Biotec Publishes Newspaper Advertisement for 42nd AGM and E-Voting
Panacea Biotec Limited published a newspaper advertisement on September 8, 2026, concerning its 42nd AGM, cut-off date, and e-voting information. The notice appeared in Business Standard and Desh Sewak, in compliance with SEBI regulations.
Read the summary - Low impact
Panacea Biotec Announces AGM on Sep 29, 2026, with Book Closure Sep 25-29
Panacea Biotec Limited will hold its 42nd Annual General Meeting on September 29, 2026, via Video Conferencing. The book closure for the AGM is from September 25 to September 29, 2026. The meeting will adopt the FY26 audited financial statements and re-appoint directors. Mr. Rajinder Singh Manku will be appointed as an independent director.
Read the summary - Low impact
Panacea Biotec Announces 42nd AGM on Sep 29, 2026; E-voting from Sep 26-28
Panacea Biotec Limited will hold its 42nd Annual General Meeting on September 29, 2026, via video conference. The Annual Report for FY2025-26 and AGM notice have been dispatched. Remote e-voting will be open from September 26 to September 28, 2026.
Read the summary - Low impact
Panacea Biotec Announces 42nd AGM on Sept 29, 2026, with E-voting Facility
Panacea Biotec's 42nd AGM is scheduled for September 29, 2026, conducted via VC/OAVM. The company will present its FY26 audited financial statements. Key agenda items include re-appointment of two directors and appointment of an independent director. Remote e-voting is available from Sept 26-28, 2026.
Read the summary - Low impact
Panacea Biotec: 3,000 Shares Dematerialized in August 2026
Panacea Biotec reported that 3,000 shares were dematerialized in August 2026. Total dematerialized shares as of August 31, 2026, reached 6,11,08,526. This comprises 5,24,39,796 via NSDL and 86,68,730 via CDSL.
Read the summary - Low impact
Panacea Biotec Announces 42nd AGM on Sep 29; Urges Email Registration
Panacea Biotec Limited will hold its 42nd AGM on September 29, 2026. Shareholders are requested to register their email addresses with the company. The notice was published in Business Standard and Desh Sewak on August 18, 2026.
Read the summary - Low impact
Panacea Biotec Publishes Q1 FY27 Financial Results
Panacea Biotec announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board approved these results on August 13, 2026, after review by the Audit Committee and statutory auditors. The full results are available on the company's and stock exchanges' websites.
Read the summary - Low impact
Panacea Biotec Announces Special Window for Share Transfer and Dematerialization
Panacea Biotec has opened a special window for the transfer and dematerialization of physical shares. The window is open from February 05, 2026, to February 04, 2027. This facility is for shares sold/purchased before April 1, 2019, where transfer was not completed.
Read the summary - Low impact
Panacea Biotec Reports Zero Shares Dematerialized in July 2026
Panacea Biotec Limited reported no shares dematerialized in July 2026. As of July 31, 2026, total dematerialized shares were 6,11,05,526 (NSDL: 5,26,65,454; CDSL: 84,40,072). A certificate from the RTA confirms these figures.
Read the summary - Medium impact
Panacea Biotec Secures UNICEF Order Worth US$8.2 Million for Polio Vaccine Supply
Panacea Biotec received a Letter of Award from UNICEF for supplying bivalent Oral Polio Vaccine (bOPV). The order is worth approximately US$8.205 million (₹78.24 Crore) and is to be executed in Calendar Year 2028. This is part of a long-term agreement with UNICEF.
Read the summary - Medium impact
Panacea Biotec Subsidiary Receives GST Show Cause Notice for ₹4.06 Crore
Panacea Biotec Pharma Limited received a GST Show Cause Notice for ₹4.06 Crore, including tax, interest, and penalty, for FY23. The notice alleges excess Input Tax Credit claim. The subsidiary is preparing a response and does not foresee adverse financial impact.
Read the summary - Medium impact
Panacea Biotec Files Appeal Against Tribunal Awards, High Court Grants Interim Relief
Panacea Biotec filed an appeal on July 16, 2026, against a fourth award by the Industrial Tribunal concerning workmen's back wages and reinstatement. The High Court granted an interim order preventing coercive steps against the company after hearing appeals against three prior awards.
Read the summary - Low impact
Panacea Biotec: No Shares Dematerialized in June 2026
Panacea Biotec Limited reported no shares were dematerialized in June 2026. As of June 30, 2026, the total dematerialized shares were 6,11,05,526 (NSDL: 5,24,78,317; CDSL: 86,27,209). This information was confirmed by the company's RTA, Skyline Financial Services Pvt. Ltd.
Read the summary - Low impact
Panacea Biotec: Compliance Certificate for Q1 FY27 Under SEBI Regulations
Panacea Biotec Limited filed a compliance certificate for the quarter ended June 30, 2026, under SEBI regulations. The certificate from its RTA confirms dematerialization of securities and registration updates.
Read the summary - Medium impact
Panacea Biotec Files Appeals Against 3 Out of 4 Industrial Tribunal Awards
Panacea Biotec Limited filed appeals against three Industrial Tribunal Awards on July 6, 2026. The company is also appealing the fourth award. The tribunal's awards included back wages, wage revision, and reinstatement. Panacea Biotec does not anticipate material adverse financial impact.
Read the summary - Low impact
Panacea Biotec Announces Special Window for Share Transfer and Dematerialization
Panacea Biotec Limited has opened a special window for physical share transfer and dematerialization, effective until February 04, 2027. This initiative, aligned with SEBI guidelines, caters to shares sold/purchased before April 1, 2019, or those with prior transfer issues. The announcement was published on June 16, 2026.
Read the summary - Low impact
Panacea Biotec Publishes Audited Q4 FY26 Financial Results in Newspapers
Panacea Biotec published its audited standalone and consolidated financial results for Q4 FY26 on June 1, 2026. These results were announced following board approval on May 30, 2026. The company also highlighted new product launches.
Read the summary - Medium impact
Panacea Biotec Board Approves FY26 Results, Appoints New Director
Panacea Biotec reported standalone net loss of ₹2,988 Lakh for FY26 and consolidated net loss of ₹1,523 Lakh. The company will not pay a dividend for FY26 due to losses. Mr. Rajinder Singh Manku was appointed as an additional non-executive independent director from July 1, 2026. DengiAll® vaccine trials are complete.
Read the summary - Medium impact
Panacea Biotec Board Approves FY26 Audited Results, No Dividend Declared, Appoints New Director
Panacea Biotec reported audited standalone and consolidated financial results for FY26. The company incurred a net loss of ₹2,988 Lakh (standalone) and ₹1,523 Lakh (consolidated) for the year ended March 31, 2026. Consequently, no dividend was declared. Mr. Rajinder Singh Manku was appointed as a non-executive independent director from July 1, 2026.
Read the summary - Low impact
Panacea Biotec Pharma Appoints Krishan Jalan & Re-appoints Manjula Upadhyay as Directors
Panacea Biotec Pharma Limited approved the appointment of Krishan Kumar Jalan as an additional non-executive independent director from July 1, 2026, until February 13, 2030. Mrs. Manjula Upadhyay was re-appointed as a non-executive independent director for five years from July 23, 2026. Both appointments require shareholder approval.
Read the summary - Low impact
Panacea Biotec Reports Nil Dematerialization in April 2026
Panacea Biotec reported no share dematerialization in April 2026. As of April 30, 2026, total dematerialized shares were 6,11,04,526 (NSDL: 5,36,44,500; CDSL: 74,60,026). This update complies with SEBI regulations.
Read the summary - Low impact
Panacea Biotec Subsidiary's Oncology Facility Disrupted by Fire
A fire incident at Panacea Biotec Pharma Limited's oncology facility in Baddi, Himachal Pradesh, has caused a temporary disruption of operations for an estimated 5 to 7 days. The company expects no material financial impact due to adequate insurance coverage.
Read the summary - Medium impact
Panacea Biotec Wins Tax Appeal, ₹9.16 Crore Demand Set Aside
Panacea Biotec Limited's appeal was allowed by the Income Tax Appellate Tribunal (ITAT) on April 29, 2026. The ITAT set aside a previous order that had raised a demand of ₹9.16 Crore. This order effectively cancels the demand and deletion of expenses for Assessment Year 2020-21.
Read the summary - Low impact
Panacea Biotec: Special Window for Share Transfer & Dematerialization Opens
Panacea Biotec opens a special window for physical share transfer and dematerialization from February 5, 2026, to February 4, 2027. This is for shares sold/purchased before April 1, 2019, with prior transfer issues. The announcement was published on April 15, 2026.
Read the summary - Medium impact
Panacea Biotec Secures ₹20.79 Crore Vaccine Supply Contract from CMSS
Panacea Biotec received a Letter of Award from Central Medical Services Society for supplying Td Vaccine. The contract value is ₹20.79 Crore. Supplies will occur between September/October 2026 and November/December 2028.
Read the summary - Medium impact
Panacea Biotec to challenge Industrial Tribunal awards impacting 23 workmen
Panacea Biotec received four Industrial Tribunal Awards concerning 23 workmen, mandating back wages and reinstatement. The company considers the awards challengeable and plans to appeal, expecting no material adverse financial impact. The dispute dates back to 2014.
Read the summary - Low impact
Panacea Biotec: No Shares Dematerialized in March 2026; Total 6.11 Crore Dematerialized
Panacea Biotec reported no share dematerialization in March 2026. As of March 31, 2026, a total of 6,11,04,526 shares were dematerialized, with 5,35,51,635 through NSDL and 75,52,891 through CDSL.
Read the summary - Low impact
Panacea Biotec Files SEBI Compliance Certificate for Q4 FY26
Panacea Biotec Limited filed a compliance certificate for Q4 FY26, confirming adherence to SEBI regulations for dematerialization of securities. The certificate was issued by the company's Registrar and Transfer Agent, Skyline Financial Services.
Read the summary - Medium impact
Panacea Biotec Tax Liability for AY 2016-17 Determined as Nil Post Rectification
Panacea Biotec received a rectified tax assessment order for AY 2016-17. The DCIT corrected errors, including double disallowances and omitted loss set-offs. The company's tax liability for the assessment year has been reduced to Nil, with no expected adverse financial impact.
Read the summary - Medium impact
Panacea Biotec Tax Liability for AY 2015-16 Determined as Nil Post Rectification
Panacea Biotec's tax liability for AY 2015-16 has been determined as Nil following a rectified Assessment Order from the DCIT, New Delhi, dated April 06, 2026. This rectifies errors in the previous order that had led to a demand of ₹45.71 Crore. The company anticipates no adverse financial impact.
Read the summary - Low impact
Panacea Biotec: Independent Director Mukul Gupta Completes Final Term
Mr. Mukul Gupta, Independent Director at Panacea Biotec, completed his second and final term on March 31, 2026. He has ceased to be a director and committee member. The company thanked him for his contributions.
Read the summary - Low impact
Panacea Biotec: Independent Director Mukul Gupta Completes Final Term
Mr. Mukul Gupta has completed his final term as an Independent Director of Panacea Biotec Limited on March 31, 2026. He has consequently ceased to be an Independent Director and a member of Board Committees. The company thanked him for his contributions.
Read the summary - Medium impact
Panacea Biotec Receives ₹22.88 Crore GST Demand Order
Panacea Biotec Limited received a GST demand order for ₹22.88 Crore, including ₹11.44 Crore in alleged non-payment of GST and ₹11.44 Crore penalty. This relates to corporate guarantees of ₹864 Crore from April 2019 to March 2022. The company has filed a writ petition and obtained an interim stay. It believes the demand is not maintainable and expects no significant financial impact.
Read the summary - Low impact
Panacea Biotec Director CA Rajesh Jain Resigns Effective June 30, 2026
CA Rajesh Jain has resigned as Non-Executive Independent Director of Panacea Biotec Limited and its subsidiary PBPL. The resignation is effective June 30, 2026, due to professional commitments and time demands. He will also step down from all board committees.
Read the summary - Medium impact
Panacea Biotec Loses Tax Appeal, ₹9.38 Crore Penalty Upheld by CIT(A)
Panacea Biotec's appeals against a ₹9.38 Crore penalty for alleged under-reporting of income were dismissed by the CIT(A) on March 25, 2026. The company plans to appeal further, stating no material impact is expected.
Read the summary - Low impact
Panacea Biotec Limited: Trading Window Closed from April 1, 2026 for FY26 Audited Results
Panacea Biotec Limited will close its trading window from April 1, 2026. This is in anticipation of the announcement of its audited financial results for the quarter and financial year ending March 31, 2026. The closure will last for 48 hours post-announcement.
Read the summary - Low impact
Panacea Biotec Subsidiary's Tax Demand Reduced to ₹0.81 Crore
Panacea Biotec Pharma Limited's tax demand has been reduced from ₹1.58 Crore to ₹0.81 Crore by the Deputy Commissioner of State Tax, Maharashtra. The subsidiary is appealing the order, and the company does not foresee any material impact on its operations or finances.
Read the summary - High impact
Panacea Biotec Wins Tax Appeal, ₹329.49 Crore Demand Quashed
Panacea Biotec Limited won a significant tax appeal. The Income Tax Appellate Tribunal (ITAT) quashed assessment orders and deleted disallowances, cancelling a demand of ₹329.49 Crore. This ruling nullifies substantial contingent tax liabilities and potential penalty exposures.
Read the summary - Medium impact
Panacea Biotec Receives ₹10.23 Crore Income Tax Demand Order
Panacea Biotec received a ₹10.23 Crore Income Tax demand order for AY 2016-17 due to disallowed expenses. The company believes the demand is non-maintainable and plans to appeal, expecting no significant financial or operational impact.
Read the summary - Low impact
Panacea Biotec Ltd. Reports Share Dematerialization Data for February 2026
Panacea Biotec Limited reported share dematerialization data for February 2026. As of February 28, 2026, a total of 6,11,04,526 shares were dematerialized, comprising 5,34,51,058 from NSDL and 76,53,468 from CDSL. This filing is in compliance with SEBI regulations.
Read the summary - Medium impact
Panacea Biotec Receives ₹45.71 Crore Income Tax Demand Order
Panacea Biotec received a ₹45.71 Crore income tax demand order for Assessment Year 2015-16 due to disallowed expenditures. The company disputes the demand, citing revised tax filings showing no tax liability. Legal recourse, including an appeal, is being pursued, with no significant financial impact anticipated.
Read the summary - Low impact
Panacea Biotec Announces Special Window for Share Transfer & Dematerialization
Panacea Biotec opens a special window from Feb 05, 2026, to Feb 04, 2027, for facilitating transfer and dematerialization of physical shares. This is for investors who sold/purchased shares before April 01, 2019, and faced issues with transfer lodgement.
Read the summary - Low impact
Panacea Biotec Publishes Unaudited Financial Results in Newspapers
Panacea Biotec Limited published its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The results were published on February 12, 2026, in Business Standard (English) and Desh Sewak (Punjabi), fulfilling SEBI listing regulations.
Read the summary - Medium impact
Panacea Biotec Q3FY26: Standalone Net Loss ₹7.36 Cr, Consolidated Net Profit ₹3.89 Cr
Panacea Biotec reported standalone net loss of ₹7.36 crore for Q3FY26, widening from ₹15.64 crore loss in Q3FY25. Consolidated net profit stood at ₹3.89 crore for Q3FY26, a turnaround from ₹14.01 crore loss in Q3FY25. Nine-month standalone net loss was ₹29.70 crore, while consolidated net profit was ₹6.16 crore.
Read the summary - Medium impact
Panacea Biotec Reports Q3 FY26 Standalone/Consolidated Unaudited Results
Panacea Biotec reported Q3 FY26 unaudited results. Standalone net loss after tax was ₹736 lakh (vs ₹965 lakh profit YoY). Consolidated net profit after tax was ₹389 lakh for the quarter. Nine-month standalone net loss was ₹2,970 lakh, and consolidated net profit was ₹389 lakh. The company is operating on a going concern basis.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio